620 – No Impact on the CNS After Switching to Dolutegravir/Lamivudine From a 3-Drug Regimen
Background Dual-drug therapy with dolutegravir/lamivudine (DTG/3TC) is effective in achieving viral suppression in the blood, but its impact on HIV infection in the central nervous system (CNS) remains insufficiently explored. In this study, we aimed to investigate its effect in the CNS through assessment of cerebrospinal fluid (CSF) in individuals switching to DTG/3TC from a…